Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878745 · ClinicalTrials.gov registry record · NA
Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle
A NA study, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT03878745 is a NA study that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 55 participants.
The verdict
NCT03878745, a NA study, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a subject single blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. the thinner commercially available Terumo Nanopass® pen needle. The study will include a minimum of 55 Japanese American study subjects with Type 1 or Type 2 diabetes.
Interventions
- DEVICE Terumo Nanopass® 34G pen needle
- DEVICE BD Nano™ PRO 32G pen needle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2019-06-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878745
The ClinicalTrials.gov registry entry for NCT03878745 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Terumo Nanopass® 34G pen needle is the first listed.
NCT03878745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878745 about?
NCT03878745 is a clinical study titled "Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle". This is a subject single blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. the thinner commercially available Terumo Nanopass® pen needle. The study will include a minimum of 55 Japanese American study subjects with ...
What is the current status of trial NCT03878745?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2019-02-11. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT03878745?
The interventions under investigation include: Terumo Nanopass® 34G pen needle (DEVICE), BD Nano™ PRO 32G pen needle (DEVICE).
Who is sponsoring clinical trial NCT03878745?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.